Σάββατο 16 Δεκεμβρίου 2017

Emerging Trends in the Treatment of Advanced Basal Cell Carcinoma

S03057372.gif

Publication date: Available online 14 December 2017
Source:Cancer Treatment Reviews
Author(s): Michael R. Migden, Anne Lynn S. Chang, Luc Dirix, Alexander J. Stratigos, John T. Lear
Basal cell carcinoma (BCC) is the most commonly diagnosed skin cancer worldwide. In most patients, BCC can be effectively treated with standard surgical excision, Mohs micrographic surgery, curettage and electrodessication, radiotherapy, and/or superficial field therapies (including 5-fluorouracil, imiquimod, and photodynamic therapy); however, a minority of patients develop advanced BCC, for which treatment can be challenging and outcomes are poorer. Advanced BCC encompasses a heterogeneous assortment of cases, including metastatic BCC as well as locally advanced BCC (for which no formal definition exists but which generally includes large, deep, aggressive, or recurrent tumors). Locally advanced BCC may be broadly categorized as cases for which (further) surgery is considered inappropriate or would be substantially disfiguring and radiation is considered inappropriate as a single modality or second-line treatment. Several therapies are being investigated for the treatment of advanced BCC. In particular, hedgehog pathway inhibitors have emerged as an important treatment option for this population. Two hedgehog pathway inhibitors—vismodegib and sonidegib—have received regulatory approval for the treatment of certain subsets of patients with advanced BCC after demonstrating clinical efficacy and safety in large, international phase 2 clinical trials. Here we review the available treatment options for BCC, focusing on the treatment of advanced BCC. Clinical data from studies evaluating vismodegib and sonidegib in patients with advanced BCC are also discussed. As more clinical trial and real-world data on the use of hedgehog pathway inhibitors become available, better-informed decisions can be made for the treatment of patients with advanced BCC.



http://ift.tt/2j6DmG4

Checkpoint inhibitors in breast cancer – current status

S03057372.gif

Publication date: Available online 14 December 2017
Source:Cancer Treatment Reviews
Author(s): Anne Polk, Inge-Marie Svane, Michael Andersson, Dorte Lisbet Nielsen
IntroductionAn increasing number of compounds directed against immune checkpoints are currently under clinical development. In this review we summarize current research in breast cancer.Material and MethodsA computer-based literature search was carried out using PubMed and EMBASE; data reported at international meetings and clinicaltrials.gov were included as well.ResultsThe obtained overall response rate of PD-1/PDL-1 monotherapy varied from 5 to 30 % in heavily pretreated triple negative breast cancer (TNBC). The median duration of progression free survival and overall survival were either not reported or short. Still responses were of long duration in a subset of patients. In the neoadjuvant setting, preliminary results including a very limited number of patients suggest high pathological response rates after combined blockade of the PD-1 pathway and chemotherapy. Multiple trials have been initiated to evaluate the combination of other anticancer agents and checkpoint inhibitors, especially in TNBC. In addition, ongoing studies aim to identify biomarkers to guide patient selection.ConclusionImmune checkpoint inhibitors have the potential to produce durable tumor remission and induce long standing anti-tumor immunity in a subgroup of breast cancer patients. However, the identification of predictive biomarkers is crucial for further development of this treatment modality.



http://ift.tt/2zhsWN1

A phase II study of 2-weeks of adjuvant whole breast/chest wall and/or regional nodal radiotherapy in patients with breast cancer

Publication date: Available online 16 December 2017
Source:International Journal of Radiation Oncology*Biology*Physics
Author(s): Budhi Singh Yadav, Suresh C. Sharma
BackgroundTo report results in terms of feasibility and early toxicity of hypofractionated adjuvant whole breast/chest wall and/or regional nodal radiotherapy in patients with breast cancer.Materials & methods: Between June 2013 and October 2014, 50 patients with breast cancer, post mastectomy or after breast conservation surgery (BCS) were prospectively included. The trial was approved by institutional ethics committee and registered with ClinicalTrials.gov, number XXXX. Patients were planned on simulator with two tangential fields to breast/chest wall and incident field to supraclavicular fossa. Radiotherapy dose delivered was 34Gy/10fractions /2 weeks followed by a boost of 10Gy/5fractions/1wk in cases with BCS. Acute skin toxicities were recorded during and after treatment according to RTOG acute radiation toxicity scoring criteria. The primary objective was to obtain estimates of rates of acute toxicities and cosmetic outcomes that could be used to design a subsequent phase III comparative study. Acute skin and late toxicities were recorded during and after treatment. Cosmetic outcomes were assessed before and after treatment and then on regular follow up. Cost benefit analysis was also done and compared with standard treatment of 35Gy/15fractions/3weeks.ResultsMedian follow up was 39 months (range 14-48 months). Mean age was 51 years (range 26-75). Left sided tumor was seen in 25(50%) patients. Total mastectomy with axillary clearance (TMAC) was done in 40(80%) and BCS in 10(20%) patients. Acute grade 2 and 3 skin toxicity was seen in 16(32%) and 1(2%) patients, respectively. In patients with BCS, grade 2 skin and subcutaneous toxicity was seen in 2(20%) and 1(10%) patients, respectively. Grade 2 edema was seen in 1(10%) patient. Cosmesis was excellent/good in 8(80%) and fair/poor in 2(20%) patients. On cost benefit analysis there was significant less financial burden on the patients with 2 weeks treatment. Disease free and overall survival at 3 years was 94% and 96%, respectively.ConclusionHypofractionated radiotherapy in 2 weeks appears to be feasible in patients with breast cancer and was associated with acute and late skin toxicity profiles that are similar to what has been observed with 3 weeks of treatment. The financial burden on the patient and family may be reduced with 2 weeks of treatment. Long-term follow up and a prospective comparative study is needed to strengthen these results. Hypofractionation may help radiation centers worldwide to meet the growing need for radiation in breast cancer, particularly in developing countries where resources are limited and patients have to travel for long distance for treatment.



http://ift.tt/2AFWhP7

Deviations from Standard Chemoradiation among Early Stage Anal Cancer Patients

Publication date: Available online 16 December 2017
Source:International Journal of Radiation Oncology*Biology*Physics
Author(s): Thomas M. Churilla, Lyudmila DeMora, Elizabeth Handorf, Nicholas G. Zaorsky, Yanqun Dong, Crystal S. Denlinger, Elin Sigurdson, Joshua E. Meyer
PurposeWe sought to evaluate factors associated with non-standard chemoradiation treatment for early stage anal cancer.MethodsWe queried the National Cancer Database for patients with squamous cell carcinoma of the anal canal, T1-T2N0M0, treated with non-palliative radiation therapy (>35Gy) from 2004- 2013. We defined "standard" radiation doses as 45-54Gy for T1 primaries and 45-59.4Gy for T2 primaries. We used multivariable logistic regression with generalized estimating equations (GEE) to test for associations with receipt of higher than standard (high dose) radiation and use of concurrent chemotherapy. The Cochran-Armitage test was used to analyze trends over time.ResultsA total of 7,800 patients met inclusion criteria. Among all patients, 82.4% received standard dose radiation, 5.2% received low dose radiation, and 12.4% received high dose radiation. The vast majority (93.5%) of patients received concurrent chemotherapy (single or multi-agent). Receipt of high dose radiation was associated with lack of single or multi-agent chemotherapy (HR [95%CI] = 2.82 [2.23-3.56]) and tumor size < 2 cm (1.89 [1.56-2.30] compared to 2-2.9 cm. Multi-agent chemotherapy administration was more frequent among patients with increasing tumor size (compared to < 2 cm): 2-2.9cm (1.38[1.17-1.64]), 3-3.9cm [1.38[1.15-1.66], and 4-5cm (1.40[1.12-1.75]). Use of multi-agent chemotherapy was less frequent among the elderly (age > 70) (0.43 [0.36-0.52]) and males (0.76 [0.66-0.86]). There was a linear trend towards increased use of standard dose radiation with time (p < 0.001) and increased use of concurrent chemotherapy with time (p < 0.001).ConclusionsOver 10% of patients with early stage anal cancer received radiation doses in excess of 54 Gy (cT1N0M0) - 59.4 Gy (cT2N0M0) and this practice varied by time, chemotherapy administration, and tumor size. Although this analysis is limited by lack of data on tumor response, wide variation in treatment practices suggest further prospective study is warranted to define the optimal radiotherapy dose for patients with early stage anal cancer.

Teaser

The optimal chemoradiation regimen for early stage (T1-T2N0M0) anal cancer patients is not well established. We sought to evaluate treatment practice patterns for early stage anal cancer patients using the National Cancer Database. Over 10% of patients with early stage anal cancer received high dose external beam radiation with concurrent chemotherapy (including 20.7% of T1 and 6.9% of T2 primary tumors), suggesting possible overtreatment of these early stage cancers.


http://ift.tt/2AG4yCG

Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models

Abstract

Increasing metabolic syndromes including type-2 diabetes mellitus, obesity, and steatohepatitis are serious problems in most countries in the world. Neurodegenerative diseases such as Alzheimer, Parkinson's, and Huntington's diseases are increasing in many countries. However, therapy for these diseases is not sufficient yet. Thus, effective chemotherapy for these diseases is being expected. Conophylline is an alkaloid isolated from the leaves of Ervatamia microphylla and related plants. It was found to induce beta-cell differentiation in the precursor pancreatic cells. Oral administration of this compound ameliorated type-2 diabetes mellitus model in mice and rats. Later, fibrosis of the pancreatic islets was found to be greatly reduced by conophylline in the pancreatic islets. It also inhibited chemically induced liver cirrhosis. Further study indicated that conophylline inhibited non-alcoholic steatohepatitis in the model mice. On the one hand, loss of autophagy often causes protein aggregation to give neural cell death. Conophylline was found to activate autophagy in cultured neural cells. Activation of autophagy ameliorated cellular models of Parkinson's and Huntington's diseases. Thus, conophylline is likely to be useful for the development of chemotherapy for metabolic and neurodegenerative diseases.



from Cancer via ola Kala on Inoreader http://ift.tt/2Bw2pgD
via IFTTT

Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models

Abstract

Increasing metabolic syndromes including type-2 diabetes mellitus, obesity, and steatohepatitis are serious problems in most countries in the world. Neurodegenerative diseases such as Alzheimer, Parkinson's, and Huntington's diseases are increasing in many countries. However, therapy for these diseases is not sufficient yet. Thus, effective chemotherapy for these diseases is being expected. Conophylline is an alkaloid isolated from the leaves of Ervatamia microphylla and related plants. It was found to induce beta-cell differentiation in the precursor pancreatic cells. Oral administration of this compound ameliorated type-2 diabetes mellitus model in mice and rats. Later, fibrosis of the pancreatic islets was found to be greatly reduced by conophylline in the pancreatic islets. It also inhibited chemically induced liver cirrhosis. Further study indicated that conophylline inhibited non-alcoholic steatohepatitis in the model mice. On the one hand, loss of autophagy often causes protein aggregation to give neural cell death. Conophylline was found to activate autophagy in cultured neural cells. Activation of autophagy ameliorated cellular models of Parkinson's and Huntington's diseases. Thus, conophylline is likely to be useful for the development of chemotherapy for metabolic and neurodegenerative diseases.



http://ift.tt/2Bw2pgD

Colon Cancer: The Road Traveled

Publication date: Available online 16 December 2017
Source:Surgical Oncology Clinics of North America
Author(s): Mark W. Arnold




http://ift.tt/2CpAsUO